H3 Biomedicine Inc., of Cambridge, Mass., said findings published in Cell Reports demonstrate that splicing factor mutations, which lead to RNA splicing dysregulation, are highly prevalent in many hematologic and solid tumor cancers, suggestive of their role as a hallmark of tumor formation and growth and opportunities for therapeutic intervention.